Study of genetic predisposition to breast and ovarian cancer in individuals with BRCA mutations

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on a cohort of individuals carrying deleterious BRCA1 or BRCA2 gene mutations to assess their genetic predispositions to breast and ovarian cancers. Participants, both men and women aged 18 and over, will complete questionnaires to gather data on their health and cancer history. The study aims to enhance understanding of how these genetic mutations influence cancer risk and outcomes. It will involve ongoing follow-up to monitor participants over time.

Why it matters

Who can join: the full rules

1. Woman or man, with or without cancer, carrying a deleterious BRCA1/BRCA2 mutation, aged 18 years and over.

   1. Woman with or without breast cancer or ovarian cancer at baseline.
   2. Man with or without breast cancer at baseline.
2. Signed consent to participation
3. Affiliation to a social security regimen, or beneficiary of such a regimen.

Exclusion Criteria:

1. A person of legal age subject to a legal protection measure, or unable to express consent.
2. Impossibility to submit to the follow-up of the test for geographical, social or psychological reasons

Where it's running

• Institut Paoli-Calmettes
  Marseille, France Recruiting

Study contacts

• Principal investigator: Catherine NOGUES, MD — Institut Paoli-Calmettes
• Study coordinator: Dominique GENRE, MD
• Email: DRCI.UP@ipc.unicancer.fr
• Phone: 33 491 22 37 78

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GEH300079 (68Ga) PET/CT scan to detect peritoneal carcinomatosis in colorectal, gastric, ovarian, and pancreatic cancers (PERISCOPE)

  This will test whether a GEH300079 (68Ga) PET/CT scan can detect peritoneal carcinomatosis in adults with colorectal, gastric, ovarian, or pancreatic ductal adenocarcinoma who have known or suspected peritoneal disease.

  Recruiting Phase 2/3 GE Healthcare · Grand Rapids, Michigan and 1 other locations · NCT07219238

• Neoadjuvant oral paclitaxel with subcutaneous pertuzumab and trastuzumab for HER2-positive breast cancer

  This trial tests whether taking oral paclitaxel together with subcutaneous pertuzumab and trastuzumab before surgery helps people with HER2-positive breast cancer achieve a complete tumor response on pathology.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Beijing, Beijing Municipality and 8 other locations · NCT07095023

• Online and in-person exercise programs for cancer survivors in Canada

  This study is testing whether online and in-person exercise programs can help cancer survivors in Canada stay active and improve their health.

  Recruiting at 5 sites University of Calgary · Calgary, Alberta and 4 other locations · NCT06960291

• Using hyperbaric oxygen to treat breast cancer before surgery

  This study is testing if hyperbaric oxygen therapy can help shrink breast tumors in women aged 18 to 60 before they have surgery.

  Recruiting Phase 1/2 Guangdong Provincial People's Hospital · Guangzhou, Guangdong and 1 other locations · NCT06811870

• Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy

  This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.

  Recruiting at 24 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Aviano and 23 other locations · NCT06805812

• Personalizing pembrolizumab for early triple-negative breast cancer patients with a complete response

  This trial will test whether people with early triple-negative breast cancer who have a complete response after pre-surgery treatment can safely stop pembrolizumab instead of continuing it for six more months.

  Recruiting at 2 sites Phase 3 Unicancer · Brussels and 1 other locations · NCT06606730

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.